C12Y 302/01129
Endo-alpha-sialidase
Official title: Endo-alpha-sialidase (3.2.1.129)
C12Y302/01129 (Endo-alpha-sialidase) appears on 7 US grants and 11 published applications in this corpus.
Search patents in C12Y- Granted patents
- 7
- Published applications
- 11
- Assignees
- 9
- Inventors
- 25
- Latest grant
- 10 May 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 2 | 2 |
| 2021 | 0 | 0 |
| 2022 | 1 | 4 |
By publication year. Applications have been published since 2001.
Recent patents
- Method of preventing aggravation of a disease involving a biological mechanism controlled by a dendritic cell immunoreceptor10 May 2022US 11,324,809 B2Tokyo University of Science Foundation
- Anti-tumor medicament based on adenovirus1 Dec 2020US 10,851,359 B2Medizinische Hochschule Hannover
- Glycosidase regimen for the treatment of chronic viral infection9 Jun 2020US 10,675,336 B2
- Composition comprising double stranded RNA that inhibits expression of NEU3 and method for treating cancer14 Sep 2010US 7,795,233 B2Miyagi Ken
- Recombinant protein having bacteriophage endosialidase enzymatic activity18 Dec 2001US 6,331,425 B1Endozyme Limited
- Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment24 Nov 2022US 2022/0370527 A1Ansun Biopharma, Inc.
- Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme28 Jul 2022US 2022/0233655 A1Research Institute At Nationwide Children's Hospital
- Optimized gene therapy targeting retinal cells21 Jul 2022US 2022/0226507 A1Research Institute At Nationwide Children's Hospital
- Destroying Cancer Cells While Maintaining Healthy Cell Integrity2 Jun 2022US 2022/0168367 A1
- Pharmaceutical Composition Containing Carbohydrate Modifying Enzyme and Method of Curing Dendritic Cell Immunoreceptor-Related Disease Using Pharmaceutical Composition20 Aug 2020US 2020/0261552 A1Tokyo University of Science Foundation
Most cited
By later US patents
- Recombinant protein having bacteriophage endosialidase enzymatic activity6US 6,331,425 B1Endozyme Limited · 2001
- KDN-cleaving sialidase isolated from hepatopancreas of mollusks3US 5,449,615 A1995
- Enzyme complex hydrolyzing bacterial cell walls derived from nocardiopsis dassonvillei1US 5,354,681 A501 Novo Industri A/S · 1994